Several countries have made unremitting efforts to develop an optimal vaccine in the fight against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the increasing occurrence of SARS-CoV-2 variants, current vaccines show decreased neutralizing activities, especially towards the Omicron variant. In this context, adding appropriate adjuvants to COVID-19 vaccines can substantially reduce the number of required doses and improve efficacy or cross-neutralizing protection. We mainly focus on research progress and achievements associated with adjuvanted COVID-19 subunit and inactivated vaccines. We further compare the advantages and disadvantages of different adjuvant formulations in order to provide a scientific reference for designing an effective strategy for future vaccine development.
【저자키워드】 COVID-19, SARS-CoV-2, Vaccine, variants, adjuvant, 【초록키워드】 coronavirus disease, Efficacy, Vaccine development, coronavirus, COVID-19 vaccine, Inactivated Vaccines, variant, omicron, SARS-CoV-2 variants, Research, dose, disadvantage, acute respiratory syndrome, subunit, effort, neutralizing activities, country, effective, IMPROVE, Occurrence, develop, caused, required, reduce, cross-neutralizing, 【제목키워드】 potent, role, Developing,